IN-CHUGAI/ELI-LILLY
27.9.2018 01:02:06 CEST | Business Wire | Press release
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, Chugai) and Eli Lilly and Company (NYSE: LLY, Lilly) today announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005486/en/
Under the terms of the agreement, Lilly will receive worldwide development and commercialization rights to OWL833. Chugai will receive an upfront payment of $50 million and is eligible for milestone payments based on achievement of certain predetermined milestones. If the molecule is successfully commercialized, Chugai would also be eligible for royalty payments.
“As a global leader in diabetes care, Lilly is committed to developing the next generation of diabetes therapies,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific Officer and President of Lilly Research Laboratories. “This exciting new opportunity from Chugai could represent a significant step forward for improving outcomes for people with diabetes.”
“We are very pleased to announce the license agreement of OWL833 with Lilly, a world-leading company in diabetes care,” said Yasushi Ito, M.D., Ph.D., Chugai’s Executive Vice President, Co-head of Project & Lifecycle Management Unit. “We believe OWL833 can be a best-in-class oral non-peptide GLP-1 receptor agonist and that its value will be further enhanced through Lilly’s clinical development to contribute to people around the world who live with diabetes.”
There will be no change to Chugai's consolidated financials forecast for the fiscal year ending December 2018 as a result of this transaction.
This transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly's 2018 non-GAAP earnings per share guidance as a result of this transaction.
This transaction is subject to potential competition authority clearances and other customary closing conditions.
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totaled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english/ .
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes and on Facebook: LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels .
Lilly Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's licensing of Chugai’s investigational medicine, OWL833. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in implementing the transaction and in drug development. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the transaction, that the molecule will be approved on the anticipated timeline or at all, or that the potential product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926005486/en/
Contact:
Chugai For Media Media Relations Group, Corporate Communications Dept., Chugai Pharmaceutical Co., Ltd. Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp *** For Investors Investor Relations Group, Corporate Communications Dept., Chugai Pharmaceutical Co., Ltd. Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp *** Lilly Lilly Media Scott MacGregor Tel: +317-440-4699 E-mail: jsmacgregor@lilly.com *** Lilly investors Kevin Hern Tel: +317-277-1838 E-mail: hern_kevin_r@lilly.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uniswap Labs and Securitize Collaborate to Unlock Liquidity Options for BlackRock’s BUIDL11.2.2026 15:00:00 CET | Press release
New integration pairs the efficiencies of Uniswap’s technology with the familiarity of traditional markets, enables near instant liquidity between BUIDL and USDC for investors Uniswap Labs, the leader in decentralized finance, and Securitize, the leader in tokenizing real-world assets (RWAs), today announced a strategic integration to make BlackRock USD Institutional Digital Liquidity Fund (BUIDL) shares available to trade via UniswapX technology. This integration will enable onchain trading of BUIDL, both unlocking new liquidity options for BUIDL holders, and marking a significant step in bridging the gap between traditional finance and DeFi. “Our mission at Labs is simple: make exchanging value cheaper, faster and more accessible,” said Hayden Adams, Uniswap Labs Founder and CEO. “Enabling BUIDL on UniswapX with BlackRock and Securitize supercharges our mission by creating efficient markets, better liquidity, and faster settlement. I’m excited to see what we build together.” Securiti
Calvin McDonald Joins The Wella Company as CEO11.2.2026 14:30:00 CET | Press release
--Industry Veteran with Track Record of Scaling Global Brands----Proven Leadership Driving Market Share and Profitable Growth-- The Wella Company, an innovative global beauty leader, today announced that Calvin McDonald has been chosen as the company’s next Chief Executive Officer, effective April 2, 2026. Calvin will also be appointed to the company’s Board of Directors and will be based in New York. Glenn Murphy will remain as Executive Chair to provide continuity as well as strategic advice to the new CEO and the leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210093439/en/ Calvin McDonald “We are delighted to welcome Calvin to The Wella Company,” said Glenn Murphy, Executive Chair. “As a three-time CEO, he brings decades of experience at industry-leading global consumer brands and retail businesses. Calvin’s proven ability to drive results through product differentiation, category expansion, and smart
Corpay Cross-Border Extends Exclusive Partnership with LIV Golf11.2.2026 14:30:00 CET | Press release
Corpay will continue to provide LIV Golf access to innovative global payments and comprehensive currency risk management solutions Corpay, Inc.* (NYSE: CPAY), a global leader in corporate payments, today announced that its Cross-Border business has entered into a multi-year agreement to extend its successful and exclusive collaboration with LIV Golf, as its Official Corporate Foreign Exchange (FX) Provider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211636852/en/ Since 2024, Corpay Cross-Border has delivered a range of corporate foreign exchange payment solutions to LIV Golf. With this multi-year extension, the League will continue to benefit from Corpay’s comprehensive currency risk management solutions and award-winning global payments platform. “Over the past two seasons, we’ve had the privilege of being the Official Corporate FX Provider for LIV Golf,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border
Energy Vault and Crusoe Announce Strategic Framework Agreement for Deployment of Crusoe Spark Modular AI Factory Units to DeliverCrusoe Cloud11.2.2026 14:30:00 CET | Press release
Multi-year framework enables rapid, phased deployments up to 25 MWbeginning in 2026, leveraging Energy Vault’s critical energy infrastructure capabilities and digital operating platform to deliver “powered shell” modular data center capacityFirst deployment planned at Energy Vault’s Snyder, Texas solar generation and energy storage technology centerto accelerate time-to-capacity for Crusoe CloudcustomersAgreement marks Energy Vault’s entry into the AI Infrastructure market, unlocking access to revenue-per-MW up to 20× higher than traditional BESS deployments, significantly accelerating Energy Vault’s EBITDA generation and scaling the Asset Vault platform Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault”), a global leader in grid-scale energy storage solution infrastructure, and Crusoe, the industry’s first vertically-integrated AI infrastructure provider, today announced a strategic framework agreement for the phased deployment of Crusoe Spark modular data centers at Energy Vaul
INNIO Secures Additional Major Order from VoltaGrid: 1.5 GW for Behind-the-Meter Power Generation11.2.2026 14:00:00 CET | Press release
INNIO and VoltaGrid have signed an agreement to supply 1.5 gigawatts (GW) of behind-the-meter power generation infrastructure, including 300 Jenbacher gas engines The order comprises Jenbacher gas engines to support AI and high‑performance computing data centers INNIO Group today announced a major order from VoltaGrid for 1.5 gigawatts (GW), reinforcing the companies’ collaboration in behind‑the‑meter (on-site) power generation for AI and high‑performance computing infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211822384/en/ INNIO's Jenbacher J624 gas engine Under the agreement, INNIO expects to supply a total of 300 Jenbacher gas engines from its Type J624 and Type J620 series. The J624 series is integrated into VoltaGrid’s proprietary QPac™ platform. The engines are packaged into 25 MW units, enabling rapid, scalable deployment for data center customers across the United States. Delivery is scheduled by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom